Cytokinetics Inc (CYTK) shareholders
Close on Nov 17, 2026Market cap $7.18BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 17,716,372 | 14.50% | 13G (passive) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 15,252,905 | 13.00% | 13G (passive) amendment | Sep 30, 2024 |
| FMR LLC Joint filing with Abigail P. Johnson (9.00%) | 11,135,192 | 9.00% | 13G (passive) amendment | Mar 31, 2026 |
| State Street Corporation | 7,143,229 | 5.10% | 13G (passive) | Sep 30, 2026 |
| Wellington Investment Advisors Holdings LLP Joint filing with Wellington Management Group LLP (5.10%), Wellington Group Holdings LLP (5.10%) | 7,116,724 | 5.10% | 13G (passive) amendment | Jun 30, 2026 |
| Vanguard Capital Management | 6,422,042 | 5.21% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CYTK | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 20,094,362 | 14.45% | $1.71B | +3,546,351 | 0.03% |
| T. Rowe Price Investment Management, Inc. | 18,718,498 | 13.46% | $1.59B | +1,194,658 | 1.05% |
| Wellington Management Group Llp | 6,931,770 | 4.99% | $590.52M | −1,077,719 | 0.10% |
| Vanguard Portfolio Management LLC | 6,711,799 | 4.83% | $571.78M | +868,017 | 0.03% |
| State Street Corp | 6,494,233 | 4.67% | $553.24M | +749,040 | 0.02% |
| Vanguard Capital Management LLC | 6,117,515 | 4.40% | $521.15M | +628,881 | 0.01% |
| FMR LLC | 5,031,782 | 3.62% | $428.66M | −5,691,358 | 0.02% |
| Avoro Capital Advisors LLC | 4,999,999 | 3.60% | $425.95M | +1,666,666 | 3.82% |
| Bank Of America Corp /De/ | 4,635,709 | 3.33% | $394.92M | +1,510,273 | 0.03% |
| Geode Capital Management, LLC | 3,712,501 | 2.67% | $316.33M | +497,086 | 0.02% |
| Rtw Investments, LP | 2,862,003 | 2.06% | $243.81M | +140,845 | 2.08% |
| Polar Capital Holdings Plc | 2,253,649 | 1.62% | $191.99M | +592,401 | 0.45% |
| Price T Rowe Associates Inc /Md/ | 1,958,946 | 1.41% | $166.88M | +374,625 | 0.02% |
| Goldman Sachs Group Inc | 1,761,588 | 1.27% | $150.07M | −444,170 | 0.01% |
| Capital Research Global Investors | 1,686,625 | 1.21% | $143.68M | +915,626 | 0.02% |
| Northern Trust Corp | 1,647,345 | 1.18% | $140.34M | +205,711 | 0.02% |
| William Blair Investment Management, LLC | 1,603,442 | 1.15% | $136.60M | +515,851 | 0.41% |
| Integral Health Asset Management, LLC | 1,600,000 | 1.15% | $136.30M | – | 5.38% |
| JPMorgan Chase & Co | 1,588,895 | 1.14% | $139.15M | +685,090 | 0.01% |
| Point72 Asset Management, L.P. | 1,587,712 | 1.14% | $135.26M | +961,610 | 0.15% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 482 | 160M | 100.0% | 95 / 235 | 103 / 47 | 32M | 17M |
| Q1 2026 | 440 | 146M | 100.0% | 80 / 176 | 134 / 64 | 32M | 22M |
| Q4 2025 | 431 | 149M | 100.0% | 106 / 145 | 132 / 47 | 20M | 14M |
| Q3 2025 | 380 | 142M | 100.0% | 101 / 126 | 103 / 26 | 17M | 12M |
| Q2 2025 | 311 | 138M | 99.1% | 28 / 144 | 103 / 71 | 19M | 18M |
| Q1 2025 | 355 | 136M | 98.1% | 56 / 141 | 109 / 44 | 14M | 9M |
| Q4 2024 | 346 | 131M | 94.5% | 48 / 118 | 136 / 47 | 12M | 18M |
| Q3 2024 | 348 | 138M | 99.0% | 47 / 144 | 97 / 41 | 27M | 12M |
| Q2 2024 | 344 | 137M | 98.3% | 43 / 156 | 93 / 85 | 31M | 15M |
| Q1 2024 | 389 | 121M | 86.7% | 104 / 127 | 121 / 61 | 33M | 30M |
| Q4 2023 | 347 | 119M | 85.5% | 122 / 76 | 107 / 23 | 23M | 14M |
| Q3 2023 | 250 | 110M | 79.1% | 26 / 95 | 78 / 27 | 9M | 7M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
517 funds held CYTK in Q2 2026, 40% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CYTK | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price Capital Appreciation Fund | 6,285,983 | 4.52% | $535.50M | 0.76% | Jun 30, 2026 |
| iShares Core S&P Mid-Cap ETF | 4,646,338 | 3.34% | $395.82M | 0.32% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,314,356 | 3.10% | $367.54M | 0.02% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,394,982 | 2.44% | $289.22M | 0.35% | Jun 30, 2026 |
| Vanguard Health Care Fund | 3,341,262 | 2.40% | $257.71M | 0.68% | Jul 31, 2026 |
| Vanguard Small-Cap Index Fund | 3,114,802 | 2.24% | $265.35M | 0.14% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 2,997,051 | 2.16% | $255.32M | 0.27% | Jun 30, 2026 |
| Fidelity OTC Portfolio | 2,269,700 | 1.63% | $175.06M | 0.41% | Jul 31, 2026 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 1,972,209 | 1.42% | $168.01M | 0.73% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,793,318 | 1.29% | $152.77M | 0.32% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,557,317 | 1.12% | $132.67M | 0.14% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,484,466 | 1.07% | $126.46M | 1.18% | Jun 30, 2026 |
| JNL/T. Rowe Price Capital Appreciation Fund | 1,446,059 | 1.04% | $123.19M | 0.81% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,444,620 | 1.04% | $111.42M | 0.33% | Jul 31, 2026 |
| T. Rowe Price Capital Appreciation Equity ETF | 1,160,888 | 0.84% | $98.90M | 1.34% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Robert I. Blum | President & CEO, Director | 282,710 | 0.20% | Nov 2, 2026 |
| Fady Ibraham Malik | EVP Research & Development | 153,902 | 0.11% | Nov 3, 2026 |
| Andrew Callos | EVP, Chief Commercial Officer | 58,555 | 0.04% | Aug 31, 2026 |
| Sung Lee | EVP, Chief Financial Officer | 63,221 | 0.05% | Jul 2, 2026 |
| Jeffrey Hessekiel | Chief Legal & Admin Officer | 107,943 | 0.08% | Mar 17, 2026 |
| Robert Wong | VP, Chief Accounting Officer | 17,889 | 0.01% | Dec 5, 2024 |
| B. Lynne Parshall | Director | 5,784 | 0.00% | Nov 12, 2026 |
| Robert Arthur Harrington | Director | 22,127 | 0.02% | Oct 20, 2026 |
| James M. Daly | Director | 3,585 | 0.00% | Oct 20, 2026 |
| Edward M. Kaye MD | Director | 10,629 | 0.01% | Oct 20, 2026 |
| Nancy Wysenski | Director | 34,089 | 0.02% | Oct 20, 2026 |
| John T. Henderson | Director | 78,795 | 0.06% | Oct 20, 2026 |
| Wendell Wierenga | Director | 35,660 | 0.03% | Oct 20, 2026 |
| Robert E. Landry | Director | 8,184 | 0.01% | Sep 15, 2026 |
| Muna Bhanji | Director | 26,361 | 0.02% | May 27, 2026 |
| Wendall Wierenga | Director | 32,345 | 0.02% | Jul 16, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| B. Lynne Parshall Director | Nov 9, 2026 | Sale(10b5-1 plan) | −2,555 | $55.26 | $141.19K | 5,784 |
| B. Lynne Parshall Director | Nov 9, 2026 | Sale(10b5-1 plan) | −2,445 | $54.17 | $132.45K | 8,339 |
| Fady Ibraham Malik EVP Research & Development | Nov 3, 2026 | Sale(10b5-1 plan) | −3,500 | $62.93 | $220.26K | 153,902 |
| Fady Ibraham Malik EVP Research & Development | Nov 3, 2026 | Option exercise | +3,500 | $7.80 | $27.30K | 157,402 |
| Robert I. Blum President & CEO, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −7,500 | $62.81 | $471.08K | 278,544 |
| Robert I. Blum President & CEO, Director | Nov 2, 2026 | Option exercise | +7,500 | $10.60 | $79.50K | 286,044 |
| Fady Ibraham Malik EVP Research & Development | Oct 20, 2026 | Sale(10b5-1 plan) | −3,500 | $64.01 | $224.04K | 153,902 |
| Fady Ibraham Malik EVP Research & Development | Oct 20, 2026 | Option exercise | +3,500 | $7.80 | $27.30K | 157,402 |
| Nancy Wysenski Director | Oct 16, 2026 | Award | +97 | $63.92 | $6.20K | 34,089 |
| Edward M. Kaye MD Director | Oct 16, 2026 | Award | +195 | $63.92 | $12.46K | 10,629 |
| Robert Arthur Harrington Director | Oct 16, 2026 | Award | +195 | $63.92 | $12.46K | 22,127 |
| James M. Daly Director | Oct 16, 2026 | Award | +195 | $63.92 | $12.46K | 3,585 |
| Wendell Wierenga Director | Oct 16, 2026 | Award | +97 | $63.92 | $6.20K | 35,660 |
| John T. Henderson Director | Oct 16, 2026 | Award | +352 | $63.92 | $22.50K | 78,712 |
| Robert I. Blum President & CEO, Director | Oct 12, 2026 | Sale(10b5-1 plan) | −7,500 | $62.88 | $471.60K | 278,544 |
| Robert I. Blum President & CEO, Director | Oct 12, 2026 | Option exercise | +7,500 | $10.60 | $79.50K | 286,044 |
| Fady Ibraham Malik EVP Research & Development | Oct 6, 2026 | Sale(10b5-1 plan) | −3,500 | $61.38 | $214.83K | 153,902 |
| Fady Ibraham Malik EVP Research & Development | Oct 6, 2026 | Option exercise | +3,500 | $7.80 | $27.30K | 157,402 |
| Robert I. Blum President & CEO, Director | Sep 28, 2026 | Sale(10b5-1 plan) | −7,500 | $65.46 | $490.95K | 278,544 |
| Robert I. Blum President & CEO, Director | Sep 28, 2026 | Option exercise | +7,500 | $10.60 | $79.50K | 286,044 |
| Fady Ibraham Malik EVP Research & Development | Sep 22, 2026 | Sale(10b5-1 plan) | −3,500 | $68.29 | $239.02K | 153,902 |
| Fady Ibraham Malik EVP Research & Development | Sep 22, 2026 | Option exercise | +3,500 | $7.80 | $27.30K | 157,402 |
| Robert E. Landry Director | Sep 15, 2026 | Sale(10b5-1 plan) | −1,000 | $72.13 | $72.13K | 8,184 |
| Robert I. Blum President & CEO, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −97,926 | $69.33 | $6.79M | 0 |
| Robert I. Blum President & CEO, Director | Sep 14, 2026 | Gift | +97,926 | – | – | 97,926 |
| Robert I. Blum President & CEO, Director | Sep 14, 2026 | Gift | −97,926 | – | – | 278,544 |
| Robert I. Blum President & CEO, Director | Sep 14, 2026 | Gift | −1,350 | – | – | 376,470 |
| Robert I. Blum President & CEO, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −7,500 | $73.44 | $550.80K | 377,820 |
| Robert I. Blum President & CEO, Director | Sep 14, 2026 | Option exercise | +7,500 | $10.60 | $79.50K | 385,320 |
| Robert E. Landry Director | Sep 11, 2026 | Sale(10b5-1 plan) | −1,000 | $74.66 | $74.66K | 9,184 |
| Fady Ibraham Malik EVP Research & Development | Sep 8, 2026 | Sale(10b5-1 plan) | −3,500 | $75.46 | $264.11K | 153,902 |
| Fady Ibraham Malik EVP Research & Development | Sep 8, 2026 | Option exercise | +3,500 | $7.80 | $27.30K | 157,402 |
| B. Lynne Parshall Director | Sep 1, 2026 | Sale(10b5-1 plan) | −5,000 | $71.48 | $357.40K | 10,784 |
| Robert I. Blum President & CEO, Director | Aug 31, 2026 | Option exercise | +7,500 | $10.60 | $79.50K | 385,320 |
| Robert I. Blum President & CEO, Director | Aug 31, 2026 | Sale(10b5-1 plan) | −7,500 | $70.24 | $526.80K | 377,820 |
| Andrew Callos EVP, Chief Commercial Officer | Aug 31, 2026 | Sale(10b5-1 plan) | −10,000 | $70.24 | $702.40K | 58,555 |
| Andrew Callos EVP, Chief Commercial Officer | Aug 31, 2026 | Option exercise | +10,000 | $23.26 | $232.60K | 68,555 |
| Fady Ibraham Malik EVP Research & Development | Aug 18, 2026 | Sale(10b5-1 plan) | −3,500 | $75.82 | $265.37K | 153,902 |
| Fady Ibraham Malik EVP Research & Development | Aug 18, 2026 | Option exercise | +3,500 | $7.80 | $27.30K | 157,402 |
| Robert I. Blum President & CEO, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −7,500 | $76.76 | $575.70K | 377,820 |
| Robert I. Blum President & CEO, Director | Aug 10, 2026 | Option exercise | +7,500 | $10.60 | $79.50K | 385,320 |
| Andrew Callos EVP, Chief Commercial Officer | Jul 30, 2026 | Sale(10b5-1 plan) | −14,000 | $79.88 | $1.12M | 58,555 |
| Andrew Callos EVP, Chief Commercial Officer | Jul 30, 2026 | Option exercise | +14,000 | $23.26 | $325.64K | 72,555 |
| Robert I. Blum President & CEO, Director | Jul 27, 2026 | Sale(10b5-1 plan) | −7,500 | $80.87 | $606.53K | 377,820 |
| Robert I. Blum President & CEO, Director | Jul 27, 2026 | Option exercise | +7,500 | $10.60 | $79.50K | 385,320 |
| Fady Ibraham Malik EVP Research & Development | Jul 21, 2026 | Sale(10b5-1 plan) | −3,500 | $80.59 | $282.07K | 153,902 |
| Fady Ibraham Malik EVP Research & Development | Jul 21, 2026 | Option exercise | +3,500 | $7.80 | $27.30K | 157,402 |
| Edward M. Kaye MD Director | Jul 15, 2026 | Award | +151 | $82.62 | $12.48K | 10,434 |
| James M. Daly Director | Jul 15, 2026 | Award | +151 | $82.62 | $12.48K | 3,390 |
| Robert Arthur Harrington Director | Jul 15, 2026 | Award | +151 | $82.62 | $12.48K | 21,932 |
| Wendell Wierenga Director | Jul 15, 2026 | Award | +75 | $82.62 | $6.20K | 35,563 |
| Nancy Wysenski Director | Jul 15, 2026 | Award | +75 | $82.62 | $6.20K | 33,992 |
| John T. Henderson Director | Jul 15, 2026 | Award | +272 | $82.62 | $22.47K | 78,360 |
| Robert I. Blum President & CEO, Director | Jul 13, 2026 | Option exercise | +7,490 | $10.60 | $79.39K | 385,310 |
| Robert I. Blum President & CEO, Director | Jul 13, 2026 | Sale(10b5-1 plan) | −7,490 | $82.02 | $614.33K | 377,820 |
| Robert I. Blum President & CEO, Director | Jul 13, 2026 | Sale(10b5-1 plan) | −10 | $82.02 | $820 | 377,820 |
| Fady Ibraham Malik EVP Research & Development | Jul 7, 2026 | Option exercise | +3,500 | $7.80 | $27.30K | 157,402 |
| Fady Ibraham Malik EVP Research & Development | Jul 7, 2026 | Sale(10b5-1 plan) | −3,500 | $86.62 | $303.17K | 153,902 |
| Robert I. Blum President & CEO, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −7,500 | $84.92 | $636.90K | 377,830 |
| Sung Lee EVP, Chief Financial Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −1,112 | $87.79 | $97.62K | 63,221 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Cytokinetics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 98,000 shares on Sep 14, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| B. Lynne Parshall Director | Nov 9, 2026 | 5,000 | $268.45K | Nov 9, 2026 | Restricted Stock Units |
| Fady Ibraham Malik Officer | Oct 20, 2026 | 16,386 | $1.03M | Oct 20, 2026 | Exercise of Stock Options |
| Robert I. Blum Director, Officer | Oct 13, 2026 | 22,500 | $1.42M | Oct 12, 2026 | Exercise of Stock Options |
| Robert I. Blum President, CEO, Director | Sep 15, 2026 | 97,926 | $7.09M | Sep 15, 2026 | Transfer |
| Robert E. Landry Director | Sep 11, 2026 | 2,000 | $147.24K | Sep 11, 2026 | Restricted Stock Units |
| B. Lynne Parshall Director | Sep 1, 2026 | 5,000 | $354.55K | Sep 1, 2026 | Restricted Stock Units |
| Andrew Callos Officer | Jul 30, 2026 | 24,000 | $1.88M | Jul 30, 2026 | Exercise of Stock Options |
| Fady Ibraham Malik Officer | Jul 7, 2026 | 24,500 | $2.10M | Jul 7, 2026 | Exercise of Stock Options |
| Robert I. Blum Director, Officer | Jul 1, 2026 | 52,500 | $4.47M | Jul 1, 2026 | Exercise of Stock Options |
| Sung Lee Officer | Jun 29, 2026 | 9,503 | $781.05K | Jun 29, 2026 | Exercise of Stock Options |
| Sung Lee Officer | Jun 26, 2026 | 6,695 | $540.96K | Jun 26, 2026 | Restricted Stock Units |
| Sung Lee Officer | Jun 24, 2026 | 38,730 | $3.10M | Jun 24, 2026 | Exercise of Stock Options |
| Edward M. Kaye MD Director | Jun 1, 2026 | 2,933 | $225.14K | Jun 1, 2026 | Restricted Stock Units |
| Wendell Wierenga Director | May 5, 2026 | 4,032 | $266.31K | May 5, 2026 | Exercise of Stock Options |
| John T. Henderson Director | May 5, 2026 | 20,000 | $1.32M | May 5, 2026 | Exercise of Stock Options |
Congress trades
5 trades in Cytokinetics reported by 2 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Gilbert Cisneros CA31 | Bought | Sep 29, 2026 | $1K–15K | Oct 12, 2026 |
| Gilbert Cisneros CA31 | Bought | Jun 30, 2026 | $1K–15K | Jul 2, 2026 |
| Gilbert Cisneros CA31 | Bought | Oct 9, 2025 | $1K–15K | Nov 18, 2025 |
| Lisa McClain MI09 · spouse | Sold | Jun 17, 2025 | $1K–15K | Aug 13, 2025 57 days late |
| Lisa McClain MI09 · spouse | Bought | Jun 11, 2025 | $1K–15K | Aug 13, 2025 63 days late |
See a number that looks wrong?